HRS-7535

HRS-7535 is a novel, oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) developed for the treatment of type 2 diabetes mellitus and obesity. It acts by stimulating the GLP-1 receptor, leading to improved glucose tolerance, enhanced insulin secretion, and reduced appetite. Clinical studies have shown that HRS-7535 has a safety and tolerability profile consistent with other GLP-1RAs, with common adverse events being mild gastrointestinal symptoms such as nausea and vomiting. Pharmacokinetic data support once-daily oral dosing. The drug has demonstrated significant reductions in body weight and plasma glucose levels in both healthy volunteers and patients with metabolic disorders[1][3][4][6].

Other names

KAI 7535KAI7535KAI-7535